NEUP Lead Drug Candidate Approval Würde

Resolves: Successful completion of Phase III trials for NEUP's lead candidate drug, demonstrating statistically significant efficacy and safety.

sec_filing· Phase III Drug Trial Success

NEUP Lead Drug Candidate Approval Würde

Derived from Neuphoria Therapeutics Inc. (NEUP) (CIK 0001191070) 10-Q filing analysis

Phase III Drug Trial Success prediction market

Implied probability (Yes): 65%
Closes: 2028-02-17

About this prediction

Resolution criteria

Successful completion of Phase III trials for NEUP's lead candidate drug, demonstrating statistically significant efficacy and safety.

No one's made a Conviction call on this yet. Be the first to call it →

Loading…